Self-Inactivating Lentiviral Vector for Safe Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene transfer technologies face challenges in delivering therapeutic molecules effectively and safely for long-term expression in target cells, particularly for cancer and genetic disorders, due to limitations in viral vectors such as adenovirus immunogenicity and short-term expression, and difficulties in delivering siRNA for RNAi-mediated therapies.
Innovation Solution
Development of a self-inactivating lentiviral transfer system that combines strategic combinations of genes with novel regulatory sequences, using a recombinant lentiviral vector system that includes a helper construct lacking a functional env protein and packaging signal, and incorporates trafficking signals like HIV-Tat or VP22 to enhance delivery and expression of therapeutic molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If adenoviral vectors are used for gene delivery, then efficient delivery to dividing and non-dividing cells is achieved, but high immunogenicity and short-term expression occur
Solution Approach 1:
The patent segments the viral vector system into multiple components: a transfer vector containing only the therapeutic gene and a packaging vector containing viral replication functions. This segmentation allows the transfer vector to be replication-deficient and less immunogenic while still achieving efficient gene delivery through the packaging vector's helper functions.
Solution Approach 2:
The patent extracts and removes the replication-competent viral genome from the delivery vector, retaining only the essential gene delivery functions. The transferred gene is packaged in a replication-deficient lentiviral vector, eliminating continuous viral replication and associated immunogenicity while maintaining delivery efficiency.
2Reliability
If self-inactivating lentiviral vectors are used, then safety is improved by eliminating replication ability, but expression duration may be limited
Solution Approach 1:
The patent applies local quality by making specific modifications only to the 3' LTR region (self-inactivation deletion) while preserving the 5' LTR promoter activity. This localized modification ensures safety by preventing replication and transduction of new cells, while the intact 5' LTR maintains long-term expression in transduced cells.
Solution Approach 2:
The patent creates asymmetry between the 5' and 3' LTR regions: the 5' LTR retains full promoter activity for sustained gene expression, while the 3' LTR contains the deletion that prevents replication. This asymmetric design resolves the contradiction between safety and long-term expression.
3Adaptability or versatility
If multiple therapeutic molecules are delivered, then synergistic therapeutic effects are achieved, but vector complexity increases
Solution Approach 1:
The patent merges multiple therapeutic gene delivery functions into a single lentiviral vector construct. The vector can simultaneously deliver multiple genes (e.g., tumor suppressor genes, RNAi molecules, dominant-negative genes) that work synergistically to inhibit tumor growth, overcoming the contradiction between versatility and complexity through the integrated nature of viral vector design.
Data Source
AI summary
The present application discloses a lentiviral transfer system which includes: (i) a self-inactivating transfer vector comprising: multiple gene units, wherein each gene unit includes a heterologous nucleic acid sequence operably linked to a regulatory nucleic acid sequence; and (ii) a helper construct which lacks a 5′ LTR, wherein the 5′ LTR has been replaced with a heterologous promoter, in which the helper construct further comprises: a lentiviral env nucleic acid sequence containing a deletion, wherein the deleted env nucleic acid sequence does not produce functional env protein; and a packaging signal contains a deletion, wherein the deleted packaging signal is nonfunctional.